MX2016014574A - El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. - Google Patents

El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.

Info

Publication number
MX2016014574A
MX2016014574A MX2016014574A MX2016014574A MX2016014574A MX 2016014574 A MX2016014574 A MX 2016014574A MX 2016014574 A MX2016014574 A MX 2016014574A MX 2016014574 A MX2016014574 A MX 2016014574A MX 2016014574 A MX2016014574 A MX 2016014574A
Authority
MX
Mexico
Prior art keywords
carbon number
alkyl
halogen atom
optionally substituted
integer
Prior art date
Application number
MX2016014574A
Other languages
English (en)
Inventor
Maurizio D'incalci
Noel Kay
Original Assignee
Oncoethix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoethix Gmbh filed Critical Oncoethix Gmbh
Publication of MX2016014574A publication Critical patent/MX2016014574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

Un método de tratamiento de cáncer de mama triple negativo en un mamífero que comprende el paso de: administrar a un paciente una cantidad farmacéuticamente aceptable de un compuesto siendo un compuesto de tienotriazolodiazepina de la fórmula (1) (ver Fórmula) en donde R1 es alquilo que tiene un número de carbonos de 1 a 4, R2 es un átomo de hidrógeno; un átomo de halógeno; o alquilo que tiene un número de carbonos de 1 a 4 opcionalmente sustituido por un átomo de halógeno o un grupo hidroxilo, R3 es un átomo de halógeno; fenilo opcionalmente sustituido por un átomo de halógeno, alquilo que tiene un número de carbonos de 1 a 4, alcoxi que tiene un número de carbonos de 1 a 4 o ciano; -NR5- (CH2)m-R6, en donde R5 es un átomo de hidrógeno o alquilo que tiene un número de carbonos de 1 a 4, m es un número entero de 0-4, y R6 es fenilo o piridilo opcionalmente sustituido por un átomo de halógeno; o -NR7-CO- (CH2)n-R8 en donde R7 es un átomo de hidrógeno o alquilo que tiene un número de carbonos de 1 a 4, n es un número entero de 0 a 2, y R8 es fenilo o piridilo opcionalmente sustituido por un átomo de halógeno y R4 es (CH2)a-CO-NH-R9 en donde a es un número entero de 1-4, y R9 es alquilo que tiene un número de carbonos de 1 a 4; hidroxialquilo que tiene un número de carbonos de 1 a 4; alcoxi que tiene un número de carbonos de 1 a 4; o fenilo o piridilo opcionalmente sustituido con alquilo que tiene un número de carbonos de 1 a 4, alcoxi que tiene un número de carbonos de 1 a 4, amino o un grupo hidroxilo o -(CH2)b-COOR10, en donde b es un número entero de 1 a 4, y R10 es alquilo que tiene un número de carbonos de 1 a 4, o una sal farmacéuticamente aceptable del mismo o un hidrato o solvato del mismo, en combinación con uno o más fármacos de quimioterapia seleccionados del grupo que consiste en inhibidores de m-TOR e inhibidores de la mitosis.
MX2016014574A 2014-05-08 2015-05-08 El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. MX2016014574A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461990457P 2014-05-08 2014-05-08
US201462012048P 2014-06-13 2014-06-13
US201462080751P 2014-11-17 2014-11-17
US201462086400P 2014-12-02 2014-12-02
US201562150044P 2015-04-20 2015-04-20
PCT/EP2015/060200 WO2015169951A1 (en) 2014-05-08 2015-05-08 Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds

Publications (1)

Publication Number Publication Date
MX2016014574A true MX2016014574A (es) 2017-02-23

Family

ID=53191652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014574A MX2016014574A (es) 2014-05-08 2015-05-08 El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.

Country Status (11)

Country Link
US (1) US9968619B2 (es)
EP (1) EP3139959A1 (es)
JP (1) JP2017519727A (es)
KR (1) KR20170002610A (es)
CN (1) CN106852120A (es)
AU (1) AU2015257658A1 (es)
BR (1) BR112016026046A8 (es)
CA (1) CA2947970A1 (es)
MX (1) MX2016014574A (es)
RU (1) RU2016147946A (es)
WO (1) WO2015169951A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035469B1 (ru) 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MX2016013851A (es) 2014-04-23 2017-07-14 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h) -onas como inhibidores de proteinas de bromodominio y extra terminal (bet).
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
IL263824B2 (en) 2016-06-20 2023-10-01 Incyte Corp Crystals in solid form in the presence of an inhibitor
WO2021180840A1 (de) * 2020-03-12 2021-09-16 Heinrich-Heine-Universität Düsseldorf Inhibition von fkbp1a zur therapie des triple-negativen mammakarzinoms
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
JP4875277B2 (ja) 2000-06-16 2012-02-15 田辺三菱製薬株式会社 放出ｐＨ域及び／又は速度制御組成物
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMOR AGENT
BR122014024883A2 (pt) 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2683734A1 (en) * 2011-03-10 2014-01-15 Institut National de la Sante et de la Recherche Medicale (INSERM) Atip3 and biologically active fragments thereof for use in the treatment of cancer
AU2013283378B2 (en) 2012-06-25 2017-07-13 Oncoethix Gmbh Method of treating lymphoma using thienotriazolodiazepine compounds
CN104717967A (zh) * 2012-06-27 2015-06-17 密苏里大学学监 通过胆固醇生物合成抑制剂的***受体β的诱导和治疗癌症的方法
US20140107107A1 (en) 2012-09-28 2014-04-17 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
EP2903616B8 (en) * 2012-10-04 2018-02-07 AB Science Use of masitinib in combination with gemcitabine for treating a subgroup of patients suffering from pancreatic cancer
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
WO2015018523A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa A novel bet-brd inhibitor for treatment of solid tumors

Also Published As

Publication number Publication date
EP3139959A1 (en) 2017-03-15
RU2016147946A (ru) 2018-06-08
CA2947970A1 (en) 2015-11-12
RU2016147946A3 (es) 2018-12-26
AU2015257658A1 (en) 2016-11-10
BR112016026046A2 (pt) 2017-08-15
US20170065607A1 (en) 2017-03-09
JP2017519727A (ja) 2017-07-20
US9968619B2 (en) 2018-05-15
KR20170002610A (ko) 2017-01-06
WO2015169951A1 (en) 2015-11-12
CN106852120A (zh) 2017-06-13
BR112016026046A8 (pt) 2021-07-20

Similar Documents

Publication Publication Date Title
MX2016014574A (es) El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
BR112014019478A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença.
CY1119227T1 (el) Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
PH12016500723A1 (en) Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EA201591890A1 (ru) Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
MX2020011810A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
NZ708563A (en) Treatment of cancers using pi3 kinase isoform modulators
SG10201805033XA (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
EA201591586A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
AR077292A1 (es) Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas
PH12015502159A1 (en) Chemical entities
RU2018113718A (ru) Новые соединения
PH12016502353A1 (en) Pharmaceutical composition
NZ767738A (en) Arginase inhibitors and methods of use thereof
RU2018102963A (ru) Производные анилинпиримидина и их применения
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
TW201613577A (en) Pharmaceutical combinations
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.